RecruitingPHASE2, PHASE3NCT07538583
Phase 2/3 Clinical Study of QRX003 Lotion in Subjects With Netherton Syndrome
Studying Congenital ichthyosiform erythroderma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Quoin Pharmaceuticals
- Intervention
- QRX003(drug)
- Enrollment
- 16 enrolled
- Eligibility
- 4 years · All sexes
- Timeline
- 2026 – 2027
Study locations (5)
- Center for Dermatology Clinical Research, Fremont, California, United States
- Yale University School of Medicine, New Haven, Connecticut, United States
- Dawes Fretzin Clinical Reseacrh Group, Indianapolis, Indiana, United States
- Beacon Clinical Research, Quincy, Massachusetts, United States
- Texas Dermatology and Laser Specialists, San Antonio, Texas, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT07538583 on ClinicalTrials.govOther trials for Congenital ichthyosiform erythroderma
Additional recruiting or active studies for the same condition.